Floatz logo

FLUOROURACILUM

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jichi Medical UniversitySmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Calcium folinate pentahydrate
Jichi Medical University
Phase 1/2CCC
yk012
Excyte Biopharma Ltd
Phase 1CC
mk-1045
MSD R&D (China) Co., Ltd.
Phase 1CC

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →